粪菌移植治疗阿尔茨海默病的研究进展OA

Alzheimer's disease(AD)is a neurodegenerative disease,and with the advent of aging,the incidence rate gradually increases,which can not be fundamentally treated by drugs clinically.Fecal microbiota transplantation(FMT)is a new method for treating Alzheimer's disease,which involves transplanting healthy microbiota from donors into the intestines of AD patients and improving their symptoms.This review summarizes the current research status of FMT treatment for AD:both animal models and preliminary clinical cases have shown that FMT can improve cognitive function,reduce A β protein deposition and tau protein phosphorylation,and alleviate neuroinflammation in the short term in terms of efficacy.The quality of the donor,the lower gastrointestinal administration pathway,and the high-frequency intensified administration regimen have been proven to be important regulatory factors for optimizing therapeutic efficacy,and combined with auxiliary measures such as methionine restriction diet can further enhance efficacy.However,there are still some challenges in the treatment of AD with FMT,such as difficulty in controlling the efficacy and unclear mecha-nisms of fecal microbiota properties,short-term and long-term safety risks,regulatory and large-scale production bar-riers.This article reviews the current research status,efficacy,key parameters,and describes the challenges and future prospects of FMT treatment for AD,in order to provide a theoretical basis for further research and application of FMT.